References9 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell Jan 7, 2000; 100(1):57–70. 10 Weinstein IB. Cancer. addiction to oncogenes—the Achil

1 Mazin B, Qumsiyeh YY.Molecular methods in oncol-
ogy: cytogenetics. In: Vincent T, Devita SH, Rosen-
berg SA (eds). Cancer: Principles and Practice of Oncology,
7th edn. Philadelphia: Lippincott,Williams &Wilkins,
2005.
2 Nowell PC. The clonal evolution of tumor cell popu-
lations. Science Oct 1, 1976; 194(4260):23–8.
3 Varmus HE. Nobel lecture. Retroviruses and onco-
genes. I. Biosci Rep Oct 1990; 10(5):413–30.
4 Todaro GJ, Huebner RJ. The viral oncogene hypoth-
esis: new evidence. Proc Natl Acad Sci U S A 1972;
69:1009–15.
5 Knudson AG, Jr. Mutation and cancer: statistical
study of retinoblastoma. Proc Natl Acad Sci U S A Apr
1971; 68(4):820–3.
6 Friend SH, Bernards R, Rogelj S et al. A human DNA
segment with properties of the gene that predisposes
to retinoblastoma and osteosarcoma. Nature Oct 16–
22, 1986; 323(6089):643–6.
7 Futreal PA, Coin L, Marshall M et al. A census of hu-
man cancer genes. Nat Rev Mar 2004; 4(3):177–83.
8 SjoblomT, Jones S,Wood LD et al. The consensus cod-
ing sequences of human breast and colorectal cancers.
Science Oct 13, 2006; 314(5797):268–74.3p21.3: identification and evaluation of the resi-
dent candidate tumor suppressor genes. The Inter-
national Lung Cancer Chromosome 3p21.3 Tumor
Suppressor Gene Consortium. Cancer Res Nov 1, 2000;
60(21):6116–33.
25 Ji L, Nishizaki M, Gao B et al. Expression of several
genes in the human chromosome 3p21.3 homozy-
gous deletion region by an adenovirus vector results
in tumor suppressor activities in vitro and in vivo.
Cancer Res May 1, 2002; 62(9):2715–20.
26 Sekido Y, Fong KM, Minna JD. Molecular genetics of
lung cancer. Annu Rev Med 2003; 54:73–87.
27 Wistuba II, Gazdar AF. Lung cancer preneoplasia.
Annu Rev Pathol Mech Dis 2006; 1(1):331–48.
28 Wistuba II, Mao L, Gazdar AF. Smoking molecular
damage in bronchial epithelium. Oncogene Oct 21,
2002; 21(48):7298–306.
29 Franklin WA, Gazdar AF, Haney J et al. Widely dis-
persed p53 mutation in respiratory epithelium. A
novel mechanism for field carcinogenesis. J Clin In-
vest Oct 15, 1997; 100(8):2133–7.
30 Walsh CP, Chaillet JR, Bestor TH. Transcription of IAP
endogenous retroviruses is constrained by cytosine
methylation. Nat Genet Oct 1998; 20(2):116–7.
31 Yoder JA, Walsh CP, Bestor TH. Cytosine methyla-
tion and the ecology of intragenomic parasites. Trends
Genet Aug 1997; 13(8):335–40.
32 Gaudet F, Hodgson JG, Eden A et al. Induction of tu-
mors in mice by genomic hypomethylation. Science
Apr 18, 2003; 300(5618):489–92.
33 Eden A, Gaudet F,Waghmare A, Jaenisch R. Chromo-
somal instability and tumors promoted by DNA hy-
pomethylation. Science Apr 18, 2003; 300(5618):455.
34 Zochbauer-Muller S, LamS, Toyooka S et al. Aberrant
methylation ofmultiple genes in the upper aerodiges-
tive tract epithelium of heavy smokers. Int J Cancer
Nov 20, 2003; 107(4):612–6.
35 Zochbauer-Muller S, Fong KM, Virmani AK,
Geradts J, Gazdar AF, Minna JD. Aberrant promoter
methylation of multiple genes in non-small cell lung
cancers. Cancer Res Jan 1, 2001; 61(1):249–55.
36 Belinsky SA, Liechty KC, Gentry FD et al. Promoter
hypermethylation of multiple genes in sputum pre-
cedes lung cancer incidence in a high-risk cohort.
Cancer Res Mar 15, 2006; 66(6):3338–44.
37 Baylin SB, Ohm JE. Epigenetic gene silencing in
cancer—a mechanism for early oncogenic pathway
addiction? Nature Rev Feb 2006; 6(2):107–16.
38 Shames DS, Minna JD, Gazdar AF. DNA methylation
in health, disease, and cancer. CurrMolMed Feb 2007;
7(1):85–102.
39 Esteller M, Corn PG, Baylin SB, Herman JG. A gene
hypermethylation profile of human cancer. Cancer Res
Apr 15, 2001; 61(8):3225–9.
40 Baylin SB, Belinsky SA, Herman JG. Aberrantmethy-
lation of gene promoters in cancer—concepts, mis-
concepts, and promise. JNatl Cancer Inst Sep 20, 2000;
92(18):1460–1.
41 Bestor TH. Unanswered questions about the role of
promotermethylation in carcinogenesis. AnnNYAcad
Sci Mar 2003; 983:22–7.
42 Chan AO, Broaddus RR, Houlihan PS, Issa JP,
Hamilton SR, Rashid A. CpG island methylation in
aberrant crypt foci of the colorectum. AmJ PatholMay
2002; 160(5):1823–30.
43 Shivapurkar N, Stastny V, Suzuki M et al. Application
of a methylation gene panel by quantitative PCR for
lung cancers. Cancer Lett Apr 25, 2006; 247(1):56–71.
44 Zochbauer-Muller S, Minna JD, Gazdar AF. Aberrant
DNA methylation in lung cancer: biological and clin-
ical implications. Oncologist 2002; 7(5):451–7.
45 Issa JP. CpG island methylator phenotype in cancer.
Nat Rev Dec 2004; 4(12):988–93.
46 Sekido Y, Fong KM, Minna JD. Progress in un-
derstanding the molecular pathogenesis of human
lung cancer. Biochim Biophys Acta Aug 19, 1998;
1378(1):F21–59.
47 Roth JA, Nguyen D, Lawrence DD et al. Retrovirus-
mediatedwild-type p53 gene transfer to tumors of pa-
tients with lung cancer. Nat Med Sep 1996; 2(9):985–
91.
48 Gabrilovich DI. INGN 201 (Advexin): adenoviral p53
gene therapy for cancer. Expert Opin Biol Ther Aug
2006; 6(8):823–32.
49 Wikman H, Nymark P, Vayrynen A et al. CDK4 is a
probable target gene in a novel amplicon at 12q13.3-
q14.1 in lung cancer. Genes Chromosomes Cancer Feb
2005; 42(2):193–9.
50 Ratschiller D, Heighway J, Gugger M et al. Cyclin D1
overexpression in bronchial epithelia of patients with
lung cancer is associated with smoking and predicts
survival. J Clin Oncol Jun 1, 2003; 21(11):2085–93.
51 Burbee DG, Forgacs E, Zochbauer-Muller S et al. Epi-
genetic inactivation of RASSF1A in lung and breast
cancers and malignant phenotype suppression. J Natl
Cancer Inst May 2, 2001; 93(9):691–9.
52 Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer
GP. Epigenetic inactivation of a RAS association do-
main family protein fromthe lung tumour suppressor
locus 3p21.3. Nat Genet Jul 2000; 25(3):315–9.
53 Kondo M, Ji L, Kamibayashi C et al. Overexpression
of candidate tumor suppressor gene FUS1 isolated